Last reviewed · How we verify
Docetaxel, Cyclophosphamide, Capecitabine
This combination regimen uses three chemotherapy agents that work together to inhibit cancer cell division and induce cell death through different mechanisms.
This combination regimen uses three chemotherapy agents that work together to inhibit cancer cell division and induce cell death through different mechanisms. Used for Breast cancer (likely early-stage or metastatic, based on typical use of this combination).
At a glance
| Generic name | Docetaxel, Cyclophosphamide, Capecitabine |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Chemotherapy combination (taxane + alkylating agent + fluoropyrimidine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel is a taxane that stabilizes microtubules and prevents cell division. Cyclophosphamide is an alkylating agent that cross-links DNA and prevents replication. Capecitabine is a fluoropyrimidine that inhibits thymidylate synthase and is incorporated into DNA/RNA. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Breast cancer (likely early-stage or metastatic, based on typical use of this combination)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Diarrhea
- Mucositis
- Peripheral neuropathy
- Alopecia
- Fatigue
Key clinical trials
- Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer (PHASE2)
- Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer (PHASE2)
- TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer (PHASE3)
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery (PHASE2)
- EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer (PHASE3)
- Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer (PHASE2)
- Neoadjuvant Treatment of Breast Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: